NASDAQ:TCBP TC Biopharm (TCBP) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free TCBP Stock Alerts $1.53 -0.04 (-2.55%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.51▼$1.6350-Day Range$1.04▼$1.9552-Week Range$0.85▼$26.80Volume71,629 shsAverage Volume3.66 million shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice Target$1,400.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get TC Biopharm alerts: Email Address TC Biopharm MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestBearish34.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.01 out of 5 stars 0.0 Analyst's Opinion Amount of Analyst CoverageTC Biopharm has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted34.94% of the outstanding shares of TC Biopharm have been sold short.Short Interest Ratio / Days to CoverTC Biopharm has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TC Biopharm has recently increased by 16.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTC Biopharm does not currently pay a dividend.Dividend GrowthTC Biopharm does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCBP. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 7 people have searched for TCBP on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows5 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TC Biopharm insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of TC Biopharm is held by insiders.Percentage Held by InstitutionsOnly 16.25% of the stock of TC Biopharm is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioTC Biopharm has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About TC Biopharm Stock (NASDAQ:TCBP)TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More TCBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCBP Stock News HeadlinesApril 6, 2024 | uk.investing.comTC BioPharm eyes expansion with CAR-NK technology LOIApril 4, 2024 | msn.comHyosung invests $1bn in green raw materials for ‘bio-spandex’April 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 4, 2024 | marketwatch.comTC BioPharm Shares Rise 63% After Letter Intent to Buy Cancer Therapy AssetsApril 4, 2024 | investorplace.comWhy Is TC Biopharm (TCBP) Stock Up 78% Today?April 4, 2024 | markets.businessinsider.comTC BioPharm Enters Non-Binding Letter Of Intent For Acquisition Of NK Platform TechnologiesApril 4, 2024 | finance.yahoo.comTCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform TechnologiesApril 2, 2024 | prnewswire.comTCBP Increasing Treatment Capacity with Expanded Manufacturing ProcessApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 19, 2024 | finance.yahoo.comTCBP Adjourns General Meeting Until a Later DateMarch 18, 2024 | finance.yahoo.comTCBP Announces Exercise of Series D Warrants For CashMarch 6, 2024 | msn.comBeyondSpring, enVVeno Medical, Aptorum Group among healthcare moversMarch 1, 2024 | finance.yahoo.comBryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"February 27, 2024 | finance.yahoo.com/C O R R E C T I O N -- TC BioPharm/February 27, 2024 | prnewswire.comTCBP Announces Shareholder Update Call on March 5th 2024February 22, 2024 | benzinga.comTC BioPharm (Holdings) Stock (NASDAQ:TCBP), Short Interest ReportFebruary 22, 2024 | msn.comOcugen, Community Health Systems among healthcare moversFebruary 22, 2024 | finance.yahoo.comTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK TrialFebruary 22, 2024 | prnewswire.comTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK TrialFebruary 15, 2024 | finance.yahoo.comTC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit EuropeFebruary 15, 2024 | prnewswire.comTC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit EuropeFebruary 14, 2024 | finance.yahoo.comTCBP Provides Shareholder Update and Highlights Upcoming MilestonesFebruary 14, 2024 | prnewswire.comTCBP Provides Shareholder Update and Highlights Upcoming MilestonesFebruary 12, 2024 | seekingalpha.comVUZI, TCBP and MANU among pre-market losersFebruary 9, 2024 | msn.comBioXcel Therapeutics, Synlogic among healthcare moversFebruary 6, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingJanuary 29, 2024 | finance.yahoo.comTC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'See More Headlines Receive TCBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCBP CUSIPN/A CIK1872812 Webwww.tcbiopharm.com Phone44-14-1433-7557FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$1,400.00 High Stock Price Target$1,400.00 Low Stock Price Target$1,400.00 Potential Upside/Downside+91,403.3%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.56 Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual Sales$4.76 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book0.31Miscellaneous Outstanding Shares680,000Free Float677,000Market Cap$1.04 million OptionableNot Optionable Beta0.32 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Bryan L. Kobel (Age 45)CEO & Director Mr. Martin E. Thorp (Age 72)CFO & Director Mr. Christopher CamarraExecutive Vice President of CommunicationsDr. Lauren Bor Ph.D.Head of Commercial Development DivisionKey CompetitorsScinai ImmunotherapeuticsNASDAQ:SCNIAcorda TherapeuticsNASDAQ:ACORSQZ BiotechnologiesNYSE:SQZAcorda TherapeuticsNASDAQ:ACORQGamida CellNASDAQ:GMDAView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 223,500 shares on 2/13/2024Ownership: 10.882%View All Institutional Transactions TCBP Stock Analysis - Frequently Asked Questions What is TC Biopharm's stock price target for 2024? 0 Wall Street analysts have issued 12 month price targets for TC Biopharm's stock. Their TCBP share price targets range from $10,000,000.00 to $0.00. On average, they predict the company's stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for TCBP or view top-rated stocks among Wall Street analysts. How have TCBP shares performed in 2024? TC Biopharm's stock was trading at $3.17 on January 1st, 2024. Since then, TCBP stock has decreased by 51.7% and is now trading at $1.53. View the best growth stocks for 2024 here. Are investors shorting TC Biopharm? TC Biopharm saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 204,500 shares, a decrease of 68.0% from the March 15th total of 638,700 shares. Based on an average daily volume of 4,520,000 shares, the short-interest ratio is currently 0.0 days. View TC Biopharm's Short Interest. When is TC Biopharm's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TCBP earnings forecast. When did TC Biopharm's stock split? TC Biopharm shares reverse split before market open on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TC Biopharm IPO? TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at $4.25 per share. EF Hutton acted as the underwriter for the IPO. How do I buy shares of TC Biopharm? Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCBP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
